6.047/6.878 Lecture 12: Small Rnas

Total Page:16

File Type:pdf, Size:1020Kb

6.047/6.878 Lecture 12: Small Rnas 6.047/6.878 Lecture 12: Small RNAs Guest Lecture by David Bartel (MIT/Whitehead/HHMI) ([email protected]) Scribed by Boyang Zhao ([email protected]) (2011) September 10, 2012 1 Contents 1 Introduction 3 1.1 ncRNA classifications........................................3 1.2 Small ncRNA.............................................3 1.3 Long ncRNA.............................................3 2 RNA Interference 5 2.1 History of discovery.........................................5 2.2 Biogenesis pathways.........................................5 2.3 Functions and silencing mechanism.................................7 2 6.047/6.878 Lecture 12: Small RNA List of Figures 1 siRNA and miRNA biogenesis pathways..............................6 2 Protein and mRNA changes following miR-223 loss........................7 1 Introduction Large-scale analyses in the 1990s using expressed sequence tags have estimated a total of 35,000 - 100,000 genes encoded by the human genome. However, the complete sequencing of human genome has surprisingly revealed that the numbers of protein-coding genes are likely to be ∼20,000 { 25,000 [12]. While this represents <2% of the total genome sequence, whole genome and transcriptome sequencing and tiling resolution genomic microarrays suggests that over >90% of the genome is still actively transcribed [8], largely as non-protein- coding RNAs (ncRNAs). Although initial speculation has been that these are non-functional transcriptional noise inherent in the transcription machinery, there has been rising evidence suggesting the important role these ncRNAs play in cellular processes and manifestation/progression of diseases. Hence these findings challenged the canonical view of RNA serving only as the intermediate between DNA and protein. 1.1 ncRNA classifications The increasing focus on ncRNA in recent years along with the advancements in sequencing technologies (i.e. Roche 454, Illumina/Solexa, and SOLiD; refer to [16] for a more details on these methods) has led to an explosion in the identification of diverse groups of ncRNAs. Although there has not yet been a consistent nomenclature, ncRNAs can be grouped into two major classes based on transcript size: small ncRNAs (<200 nucleotides) and long ncRNAs (lncRNAs) (≥200 nucleotides) (Table 11)[6,8, 13, 20, 24]. Among these, the role of small ncRNAs microRNA (miRNA) and small interfering RNA (siRNA) in RNA silencing have been the most well-documented in recent history. As such, much of the discussion in the remainder of this chapter will be focused on the roles of these small ncRNAs. But first, we will briefly describe the other diverse set of ncRNAs. 1.2 Small ncRNA For the past decades, there have been a number of well-studied small non-coding RNA species. All of these species are either involved in RNA translation (transfer RNA (tRNA)) or RNA modification and processing (small nucleolar RNA (snoRNA) and small nuclear RNA (snRNA)). In particular, snoRNA (grouped into two broad classes: C/D Box and H/ACA Box, involved in methylation and pseudouridylation, respectively) are localized in the nucleous and participates in rRNA processing and modification. Another group of small ncRNAs are snRNAs that interact with other proteins and with each other to form splicesomes for RNA splicing. Remarkably, these snRNAs are modified (methylation and pseudouridylation) by another set of small ncRNAs - small Cajal body-specific RNAs (scaRNAs), which are similar to snoRNA (in sequence, structure, and function) and are localized in the Cajal body in the nucleus. Yet in another class of small ncRNAs, guide RNAs (gRNAs) have been shown predominately in trypanosomatids to be involved in RNA editing. Many other classes have also been recently proposed (see Table 1) although their functional roles remain to be determined. Perhaps the most widely studied ncRNA in the recent years are microRNAs (miRNAs), involved in gene silencing and responsible to the regulation of more than 60% protein-coding genes [6]. Given the extensive work that has been focused on RNAi and wide range of RNAi-based applications that have emerged in the past years, the next section (RNA Interference) will be entirely devoted to this topic. 1.3 Long ncRNA Long ncRNAs (lncRNAs) make up the largest portion of ncRNAs [6]. However the emphasis placed on the study of long ncRNA has only been realized in the recent years. As a result, the terminology for this family of 1TODO: @scribe: In Table 1, ncRNAs with functions labeled not clear have not yet been extensively searched in literature. There can be recent studies that suggest the functional roles of these ncRNAs. 3 6.047/6.878 Lecture 12: Small RNA Table 1: ncRNA classifications (based on [6,8, 13, 20, 24]) Name Abbreviation Function Housekeeping RNAs Ribosomal RNA rRNA translation Transfer RNA tRNA translation Small nucleolar RNA snoRNA (∼60-220 nt) rRNA modification Small Cajal body-specific RNA scaRNA splicesome modification Small nuclear RNA snRNA (∼60-300 nt) RNA splicing Guide RNA gRNA RNA editing Small ncRNAs (<200 nt) MicroRNA miRNA (∼19-24 nt) RNA silencing Small interfering RNA siRNA (∼21-22 nt) RNA silencing Piwi interacting RNA piRNA (∼26-31 nt) Transposon silencing, epigenetic regulation Tiny transcription initiation RNA tiRNA (∼17-18 nt) Transcriptional regulation? Promoter-associated short RNA PASR (∼22-200 nt) unknown Transcription start site antisense RNA TSSa-RNA (∼20-90 nt) Transcriptional maintainence? Termini-associated short RNA TASR not clear Antisense termini associated short RNA aTASR not clear Retrotransposon-derived RNA RE-RNA not clear 3'UTR-derived RNA uaRNA not clear x-ncRNA x-ncRNA not clear Small NF90-associated RNA snaR not clear Unusually small RNA usRNA not clear Vault RNA vtRNA not clear Human Y RNA hY RNA not clear Long ncRNAs (≥200 nt) Large intergenic ncRNA lincRNA Epigenetics regulation Transcribed ultraconserved regions T-UCR miRNA regulation? Pseudogenes none miRNA regulation? Promoter upstream transcripts PROMPT Transcriptional activation? Telomeric repeat-containing RNA TERRA telomeric heterochromatin main- tenance GAA-repeat containing RNA GRC-RNA not clear Enhancer RNA eRNA not clear Long intronic ncRNA none not clear Antisense RNA aRNA not clear Promoter-associated long RNA PALR not clear Stable excised intron RNA none not clear Long stress-induced non-coding transcripts LSINCT not clear ncRNAs are still in its infancy and oftentimes inconsistent in the literature. This is also in part complicated by cases where some lncRNAs can also serve as transcripts for the generation of short RNAs. In light of these confusions, as discussed in the previous chapter, lncRNA have been arbitrarily defined as ncRNAs with size greater than 200 nts (based on the cut-off in RNA purification protocols) and can be broadly categorized into: sense, antisense, bidirectional, intronic, or intergenic [19]. For example, one particular class of lncRNA called long intergenic ncRNA (lincRNA) are found exclusively in the intergenic region and possesses chromatin modifications indicative of active transcription (e.g. H3K4me3 at the transcriptional 4 6.047/6.878 Lecture 12: Small RNA start site and H3K36me3 throughout the gene region) [8]. Despite the recent rise of interest in lncRNAs, the discovery of the first lncRNAs (XIST and H19 ), based on searching cDNA libraries, dated back to the 1980s and 1990s before the discovery of miRNAs [3,4]. Later studies demonstrated the association of lncRNAs with polycomb group proteins, suggesting potential roles of lncRNAs in epigenetic gene silencing/activation [19]. Another lncRNA, HOX Antisense Intergenic RNA (HOTAIR), was recently found to be highly upregulated in metastatic breast tumors [11]. The association of HOTAIR with the polycomb complex again supports a potential unified role of lncRNAs in chromatin remodeling/epigenetic regulation (in either a cis-regulatory (XIST and H19 ), or trans-regulatory (e.g. HOTAIR) fashion) and disease etiology. Recent studies have also identified HULC and pseudogene (transcript resembling real genes but contains mutations that prevent their translation into functional proteins) PTENP1 that may function as a decoy in binding to miRNAs to reduce the overall effectiveness of miRNAs [18, 25]. Other potential roles of lncRNAs remains to be explored. Nevertheless, it is becoming clear that lncRNAs are less likely to be the result of transcriptional noise, but may rather serve critical role in the control of cellular processes. 2 RNA Interference RNA interference has been one of the most significant and exciting discoveries in recent history. The impact of this discovery is enormous with applications ranging from knockdown and loss-of-function studies to the generation of better animal models with conditional knockdown of desired gene(s) to large-scale RNAi-based screens to aid drug discovery. 2.1 History of discovery The discovery of the gene silencing phenomenon dated back as early as the 1990s with Napoli and Jorgensen demonstrating the down-regulation of chalcone synthase following introduction of exogenous transgene in plants [17]. Similar suppression was subsequently observed in other systems [10, 22]. In another set unrelated work at the time, Lee et al. identified in a genetic screen that endogenous lin-4 expressed a non-protein- coding product that is complementary to the lin-14 gene and controlled the timing of larval development (from first to second larval state) in C. elegans [15]. We now know this as the first miRNA to be discovered. In 2000, another miRNA, let-7, was discovered in the same
Recommended publications
  • Patenting Interfering RNA
    Patenting Interfering RNA J. Douglas Schultz SPE Art Unit 1635 (571) 272-0763 [email protected] Oligonucleotide Inhibitors: Mechanisms of Action RNAi - Mechanism of Action • dsRNA induces sequence-specific degradation of homologous gene transcripts • RISC metabolizes dsRNA to small 21-23- nucleotide siRNAs – RISC contains dsRNase (“Dicer”), ssRNase (Argonaut 2 or Ago2) • RISC utilizes antisense strand as “guide” to find cleavable target siRNA Mechanism of Action miRNA Mechanism of Action Interfering RNA Glossary of Terms • RNAi – RNA interference • dsRNA – double stranded RNA • siRNA – small interfering RNA, double stranded, 21-23 nucleotides • shRNA – short hairpin RNA (doubled stranded by virtue of a ssRNA folding back on itself) • miRNA – micro RNA • RISC – RNA-induced silencing complex – Dicer – RNase endonuclease siRNA miRNA • Exogenously delivered • Endogenously produced • 21-23mer dsRNA • 21-23mer dsRNA • Acts through RISC • Acts through RISC • Induces homologous target • Induces homologous target cleavage cleavage • Perfect sequence match • Imperfect sequence match – Results in target degradation – Results in translation arrest RNAi Patentability issues Sample Claims: • A siRNA that inhibits expression of a nucleic acid encoding protein X. OR • A siRNA comprising a 2’-modification, wherein said modification comprises 2’-fluoro, 2’-O-methyl, or 2’- deoxy. (Note: no target recited) OR • A method of reducing tumor cell growth comprising administering siRNA targeting protein X. RNAi Patentability Issues 35 U.S.C. 101 – Utility • Credible/Specific/Substantial/Well Established. • Used to attempt modulation of gene expression in human diseases • Routinely investigate gene function in a high throughput fashion or to (see Rana RT, Nat. Rev. Mol. Cell Biol. 2007, Vol. 8:23-36).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0086860 A1 Sohail (43) Pub
    US 20040O86860A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0086860 A1 Sohail (43) Pub. Date: May 6, 2004 (54) METHODS OF PRODUCING RNAS OF Publication Classification DEFINED LENGTH AND SEQUENCE (51) Int. Cl." .............................. C12Q 1/68; C12P 19/34 (76) Inventor: Muhammad Sohail, Marston (GB) (52) U.S. Cl. ............................................... 435/6; 435/91.2 Correspondence Address: MINTZ, LEVIN, COHN, FERRIS, GLOWSKY (57) ABSTRACT AND POPEO, PC. ONE FINANCIAL CENTER Methods of making RNA duplexes and single-stranded BOSTON, MA 02111 (US) RNAS of a desired length and Sequence based on cleavage of RNA molecules at a defined position, most preferably (21) Appl. No.: 10/264,748 with the use of deoxyribozymes. Novel deoxyribozymes capable of cleaving RNAS including a leader Sequence at a (22) Filed: Oct. 4, 2002 Site 3' to the leader Sequence are also described. Patent Application Publication May 6, 2004 Sheet 1 of 2 US 2004/0086860 A1 DNA Oligonucleotides T7 Promoter -TN-- OR 2N-2-N-to y Transcription Products GGGCGAAT-N-UU GGGCGAAT-N-UU w N Deoxyribozyme Cleavage - Q GGGCGAAT -------' Racction GGGCGAAT N-- UU N-UU ssRNA products N-UU Anneal ssRNA UU S-2N- UU siRNA product FIGURE 1: Flowchart summarising the procedure for siRNA synthesis. Patent Application Publication May 6, 2004 Sheet 2 of 2 US 2004/0086860 A1 Full-length transcript 3'-digestion product 5'-digestion product (5'GGGCGAATA) A: Production of single-stranded RNA templates by in vitro transcription and digestion With a deoxyribozyme V 2- 2 V 22inv 22 * 2 &3 S/AS - 88.8x, *...* or as IGFR -- is as 4.
    [Show full text]
  • Small Interfering RNA-Mediated Translation Repression Alters Ribosome Sensitivity to Inhibition by Cycloheximide in Chlamydomonas Reinhardtii
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Dissertations and Theses in Biological Sciences Biological Sciences, School of Spring 2013 Small Interfering RNA-Mediated Translation Repression Alters Ribosome Sensitivity to Inhibition by Cycloheximide in Chlamydomonas reinhardtii Xinrong Ma University of Nebraska-Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/bioscidiss Part of the Biology Commons, Cellular and Molecular Physiology Commons, Microbiology Commons, and the Molecular Genetics Commons Ma, Xinrong, "Small Interfering RNA-Mediated Translation Repression Alters Ribosome Sensitivity to Inhibition by Cycloheximide in Chlamydomonas reinhardtii" (2013). Dissertations and Theses in Biological Sciences. 51. https://digitalcommons.unl.edu/bioscidiss/51 This Article is brought to you for free and open access by the Biological Sciences, School of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Dissertations and Theses in Biological Sciences by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. SMALL INTERFERING RNA-MEDIATED TRANSLATION REPRESSION ALTERS RIBOSOME SENSITIVITY TO INHIBITION BY CYCLOHEXIMIDE IN CHLAMYDOMONAS REINHARDTII by Xinrong Ma A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Biological Sciences Under the Supervision of Professor Heriberto Cerutti Lincoln, Nebraska May, 2013 SMALL INTERFERING RNA-MEDIATED TRANSLATION REPRESSION ALTERS RIBOSOME SENSITIVITY TO INHIBITION BY CYCLOHEXIMIDE IN CHLAMYDOMONAS REINHARDTII Xinrong Ma, Ph.D. University of Nebraska, 2013 Advisor: Heriberto Cerutti RNA interference (RNAi) is an evolutionarily conserved gene silencing mechanism in eukaryotes, with regulatory roles in a variety of biological processes, including cell cycle, cell differentiation, physiological and metabolic pathways, and stress responses.
    [Show full text]
  • Retroviral Delivery of Small Interfering RNA Into Primary Cells
    Retroviral delivery of small interfering RNA into primary cells Gregory M. Barton and Ruslan Medzhitov* Section of Immunobiology and The Howard Hughes Medical Institute, Yale University School of Medicine, 310 Cedar Street, New Haven, CT 06520 Communicated by Peter Cresswell, Yale University School of Medicine, New Haven, CT, October 2, 2002 (received for review August 9, 2002) RNA interference is an evolutionarily conserved process in which gene was replaced with the human CD4 gene, which was cloned recognition of double-stranded RNA ultimately leads to posttran- from splenic cDNA. To eliminate any potential signaling, a scriptional suppression of gene expression. This suppression is premature stop codon was introduced after amino acid 425, just mediated by short (21- to 22-nt) small interfering RNAs (siRNAs), after the transmembrane domain. The human H1 promoter was which induce degradation of mRNA based on complementary base cloned from genomic DNA and inserted either upstream of the pairing. The silencing of gene expression by siRNAs is emerging cytomegalovirus (CMV) promoter (RVH1) by using previously rapidly as a powerful method for genetic analysis. Recently, several introduced XhoI and EcoRI sites or within the 3Ј LTR by groups have reported systems designed to express siRNAs in using SalI. The oligonucleotides encoding the human p53 mammalian cells through transfection of either oligonucleotides or siRNA, described by Brummelkamp et al. (6), were 5Ј-GATC- plasmids encoding siRNAs. Because these systems rely on trans- CCCGACTCCAGTGGTAATCTACTTCAAGAGAGTA- fection for delivery, the cell types available for study are restricted GATTACCACTGGAGTCTTTTTGGAAC-3Ј and 5Ј-TCGA- generally to transformed cell lines. Here, we describe a retroviral GTTCCAAAAAGACTCCAGTGGTAATCTACTCTCTTG- system for delivery of siRNA into cells.
    [Show full text]
  • Viral Vectors Applied for Rnai-Based Antiviral Therapy
    viruses Review Viral Vectors Applied for RNAi-Based Antiviral Therapy Kenneth Lundstrom PanTherapeutics, CH1095 Lutry, Switzerland; [email protected] Received: 30 July 2020; Accepted: 21 August 2020; Published: 23 August 2020 Abstract: RNA interference (RNAi) provides the means for alternative antiviral therapy. Delivery of RNAi in the form of short interfering RNA (siRNA), short hairpin RNA (shRNA) and micro-RNA (miRNA) have demonstrated efficacy in gene silencing for therapeutic applications against viral diseases. Bioinformatics has played an important role in the design of efficient RNAi sequences targeting various pathogenic viruses. However, stability and delivery of RNAi molecules have presented serious obstacles for reaching therapeutic efficacy. For this reason, RNA modifications and formulation of nanoparticles have proven useful for non-viral delivery of RNAi molecules. On the other hand, utilization of viral vectors and particularly self-replicating RNA virus vectors can be considered as an attractive alternative. In this review, examples of antiviral therapy applying RNAi-based approaches in various animal models will be described. Due to the current coronavirus pandemic, a special emphasis will be dedicated to targeting Coronavirus Disease-19 (COVID-19). Keywords: RNA interference; shRNA; siRNA; miRNA; gene silencing; viral vectors; RNA replicons; COVID-19 1. Introduction Since idoxuridine, the first anti-herpesvirus antiviral drug, reached the market in 1963 more than one hundred antiviral drugs have been formally approved [1]. Despite that, there is a serious need for development of novel, more efficient antiviral therapies, including drugs and vaccines, which has become even more evident all around the world today due to the recent coronavirus pandemic [2].
    [Show full text]
  • Advances in Oligonucleotide Drug Delivery
    REVIEWS Advances in oligonucleotide drug delivery Thomas C. Roberts 1,2 ✉ , Robert Langer 3 and Matthew J. A. Wood 1,2 ✉ Abstract | Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing. As such, these molecules have potential therapeutic applications for myriad indications, with several oligonucleotide drugs recently gaining approval. However, despite recent technological advances, achieving efficient oligonucleotide delivery, particularly to extrahepatic tissues, remains a major translational limitation. Here, we provide an overview of oligonucleotide-based drug platforms, focusing on key approaches — including chemical modification, bioconjugation and the use of nanocarriers — which aim to address the delivery challenge. Oligonucleotides are nucleic acid polymers with the In addition to their ability to recognize specific tar- potential to treat or manage a wide range of diseases. get sequences via complementary base pairing, nucleic Although the majority of oligonucleotide therapeutics acids can also interact with proteins through the for- have focused on gene silencing, other strategies are being mation of three-dimensional secondary structures — a pursued, including splice modulation and gene activa- property that is also being exploited therapeutically. For tion, expanding the range of possible targets beyond example, nucleic acid aptamers are structured
    [Show full text]
  • Ribozyme-Enhanced Single-Stranded Ago2-Processed Interfering RNA Triggers Efficient Gene Silencing with Fewer Off-Target Effects
    ARTICLE Received 9 Dec 2014 | Accepted 21 Aug 2015 | Published 12 Oct 2015 DOI: 10.1038/ncomms9430 OPEN Ribozyme-enhanced single-stranded Ago2-processed interfering RNA triggers efficient gene silencing with fewer off-target effects Renfu Shang1,2,3, Fengjuan Zhang1,2,3, Beiying Xu1,2,3, Hairui Xi4, Xue Zhang1,2,3, Weihua Wang1,2,3 & Ligang Wu1,2,3 Short-hairpin RNAs (shRNAs) are widely used to produce small-interfering RNAs (siRNAs) for gene silencing. Here we design an alternative siRNA precursor, named single-stranded, Argonaute 2 (Ago2)-processed interfering RNA (saiRNA), containing a 16–18 bp stem and a loop complementary to the target transcript. The introduction of a self-cleaving ribozyme derived from hepatitis delta virus to the 30 end of the transcribed saiRNA dramatically improves its silencing activity by generating a short 30 overhang that facilitates the efficient binding of saiRNA to Ago2. The same ribozyme also enhances the activity of Dicer-dependent shRNAs. Unlike a classical shRNA, the strand-specific cleavage of saiRNA by Ago2 during processing eliminates the passenger strand and prevents the association of siRNA with non-nucleolytic Ago proteins. As a result, off-target effects are reduced. In addition, saiRNA exhibits less competition with the biogenesis of endogenous miRNAs. Therefore, ribozyme-enhanced saiRNA provides a reliable tool for RNA interference applications. 1 National Center for Protein Science Shanghai, State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China. 2 Shanghai Science Research Center, Chinese Academy of Sciences, Shanghai 201204, China.
    [Show full text]
  • Ribonucleic Acid (RNA)
    AccessScience from McGraw-Hill Education Page 1 of 11 www.accessscience.com Ribonucleic acid (RNA) Contributed by: Michael W. Gray, Ann L. Beyer Publication year: 2014 One of the two major classes of nucleic acid, mainly involved in translating the genetic information carried in deoxyribonucleic acid (DNA) into proteins. Various types of ribonucleic acids (RNAs) [see table] function in protein synthesis: transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs) function in the synthesis of all proteins, whereas messenger RNAs (mRNAs) are a diverse set, with each member specifically directing the synthesis of one protein. Messenger RNA is the intermediate in the usual biological pathway of DNA → RNA → protein. However, RNA is a very versatile molecule. Other types of RNA serve other important functions for cells and viruses, such as the involvement of small nuclear RNAs (snRNAs) in mRNA splicing. In some cases, RNA performs functions typically considered DNA-like, such as serving as the genetic material for certain viruses, or roles typically carried out by proteins, such as RNA enzymes or ribozymes. See also: DEOXYRIBONUCLEIC ACID (DNA); NUCLEIC ACID. Structure and synthesis RNA is a linear polymer of four different nucleotides (Fig. 1). Each nucleotide is composed of three parts: a five-carbon sugar known as ribose; a phosphate group; and one of four bases attached to each ribose, that is, adenine (A), cytosine (C), guanine (G), or uracil (U). The combination of base and sugar constitutes a nucleoside. The structure of RNA is basically a repeating chain of ribose and phosphate moieties, with one of the four bases attached to each ribose.
    [Show full text]
  • RNA-Based Therapeutics: Current Progress and Future Prospects
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Chemistry & Biology Review RNA-Based Therapeutics: Current Progress and Future Prospects John C. Burnett1 and John J. Rossi1,* 1Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA *Correspondence: [email protected] DOI 10.1016/j.chembiol.2011.12.008 Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases ranging from genetic disorders to HIV infection to various cancers. These emerging drugs, which include therapeutic ribozymes, aptamers, and small interfering RNAs (siRNAs), demonstrate the unprece- dented versatility of RNA. However, RNA is inherently unstable, potentially immunogenic, and typically requires a delivery vehicle for efficient transport to the targeted cells. These issues have hindered the clinical progress of some RNA-based drugs and have contributed to mixed results in clinical testing. Nevertheless, promising results from recent clinical trials suggest that these barriers may be overcome with improved synthetic delivery carriers and chemical modifications of the RNA therapeutics. This review focuses on the clinical results of siRNA, RNA aptamer, and ribozyme therapeutics and the prospects for future successes. Introduction synthesizing modified RNA and DNA molecules have increased Since the milestone
    [Show full text]
  • Plant Non-Coding Rnas: Origin, Biogenesis, Mode of Action and Their Roles in Abiotic Stress
    International Journal of Molecular Sciences Review Plant Non-Coding RNAs: Origin, Biogenesis, Mode of Action and Their Roles in Abiotic Stress Joram Kiriga Waititu 1, Chunyi Zhang 1, Jun Liu 2 and Huan Wang 1,* 1 Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China; [email protected] (J.K.W.); [email protected] (C.Z.) 2 National Key Facility for Crop Resources and Genetic Improvement, Institute of Crop Science, Chinese Academy of Agricultural Sciences, Beijing 100081, China; [email protected] * Correspondence: [email protected] Received: 13 October 2020; Accepted: 4 November 2020; Published: 9 November 2020 Abstract: As sessile species, plants have to deal with the rapidly changing environment. In response to these environmental conditions, plants employ a plethora of response mechanisms that provide broad phenotypic plasticity to allow the fine-tuning of the external cues related reactions. Molecular biology has been transformed by the major breakthroughs in high-throughput transcriptome sequencing and expression analysis using next-generation sequencing (NGS) technologies. These innovations have provided substantial progress in the identification of genomic regions as well as underlying basis influencing transcriptional and post-transcriptional regulation of abiotic stress response. Non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), short interfering RNAs (siRNAs), and long non-coding RNAs (lncRNAs), have emerged as essential regulators of plants abiotic stress response. However, shared traits in the biogenesis of ncRNAs and the coordinated cross-talk among ncRNAs mechanisms contribute to the complexity of these molecules and might play an essential part in regulating stress responses. Herein, we highlight the current knowledge of plant microRNAs, siRNAs, and lncRNAs, focusing on their origin, biogenesis, modes of action, and fundamental roles in plant response to abiotic stresses.
    [Show full text]
  • The Specifics of Small Interfering RNA Specificity
    COMMENTARY The specifics of small interfering RNA specificity Andrew Dillin* Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037 he discovery of transgene silenc- ing in plants and double- stranded RNA (dsRNA) inter- ference in the worm TCaenorhabditis elegans has led to the latest revolution in molecular biology, RNA interference (RNAi). Over 10 years ago it was noted that several trans- genic plant lines each containing the same ectopic transgene not only failed to be expressed but also inhibited the expression of the endogenous gene (1). Similarly, a determined Craig Mello and Andy Fire (2), attempting to reduce gene function using antisense RNA in the worm, discovered a minor contami- nant in their antisense RNA prepara- tions effectively and repeatedly reduced expression of the endogenous gene. In both cases, dsRNA homologous to the gene of interest was responsible for these observations. In the last 4 years, these discoveries have been extended to include protozoa, fungi, and mammals. What is RNAi? RNAi is a highly con- served mechanism found in almost all eukaryotes and believed to serve as an antiviral defense mechanism. The mo- lecular details are becoming clear from combined genetic and biochemical ap- proaches (reviewed in refs. 3 and 4). On entry into the cell, the dsRNA is cleaved by an RNase III like enzyme, Dicer, into small interfering (21- to 23- nt) RNAs (siRNAs) (5–8) (Fig. 1). Bio- chemical evidence indicates the siRNAs are incorporated into a multisubunit protein complex, the RNAi-induced si- Fig. 1.
    [Show full text]
  • Study of Small Non-Coding Rnas in Plants by Developing Novel Pipelines
    Study of small non-coding RNAs in plants by developing novel pipelines Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) der Naturwissenschaftlichen Fakultät III Agrar- und Ernährungswissenschaften, Geowissenschaften und Informatik der Martin–Luther–Universität Halle–Wittenberg, vorgelegt von Frau Deblina Patra Bhattacharya Geb. am 21. August 1983 in Krishnanagar Nadia Gutachter: Prof. Dr. Ivo Große Prof. Dr. Peter F. Stadler Prof. Dr. Ivo Hofacker Datum der Verteidigung: 27.04.2017 Eidesstattliche Erkl¨arung / Declaration under Oath i Ich erkl¨are an Eides statt, dass ich die Arbeit selbstst¨andig und ohne fremde Hilfe verfasst, keine anderen als die von mir angegebenen Quellen und Hilfsmittel benutzt und die den benutzten Werken w¨ortlich oder inhaltlich entnommenen Stellen als solche kenntlich gemacht habe. I declare under penalty of perjury that this thesis is my own work entirely and has been written without any help from other people. I used only the sources mentioned and included all the citations correctly both in word or content. Signature: Date: Abstract ii Nowadays, high throughput sequencing technologies have become essential in stud- ies on genomics, epigenomics, and transcriptomics since they are capable of se- quencing multiple DNA molecules in parallel, enabling hundreds of millions of DNA molecules to be sequenced at a time. This is a great advantage which allows HTS to be used to create large data sets, generating more comprehensive insights into the cellular genomic and transcriptomic signatures of various diseases and developmental stages. Small non-coding RNAs make up much of the RNA content of a cell and have the potential to regulate gene expression on many different levels.
    [Show full text]